[ad_1]
Groundbreaking results from a recent study demonstrate a 96% overall survival rate for melanoma patients using a new vaccine treatment. Moderna, in partnership with Merck and Co, have made strides in the fight against skin cancer by combining their innovative cancer vaccine with the well-known cancer treatment, Keytruda.
Detailed data from a study involving 157 patients shows a significant improvement in survival rates two-and-a-half years after treatment with the vaccine-Keytruda combo. Specifically, the combination treatment resulted in a survival rate of 96%, while Keytruda alone resulted in a 90.2% survival rate.
Additionally, recurrence-free survival was 75% for those receiving the vaccine alongside Keytrudacompared to 55.6% for those on Keytruda monotherapy. An earlier report in December highlighted a 49% decrease in the risk of recurrence or death in patients utilizing the combined treatment as opposed to just Keytruda, with nearly a three-year median follow-up.
The collaborative effort between Merck and Moderna, which began in 2016, continues as they have launched a larger late-stage study to further evaluate their combined treatment.
This partnership represents a wider industry trend focusing on uniting robust immune system-activating drugs with mRNA vaccine technologies that provide cells with the protein construction blueprints tailored for individual patients.
Stay updated on news from both the UK and across the globe by joining Sky News on WhatsApp
Professor Georgina Long of Melanoma Institute Australia expressed optimism, noting the international impact the trial results could have on cancer treatments. She described the results as “transformative” for melanoma treatment and potentially influential for other cancers as well.
Prof Long also emphasized the pioneering nature of the phase III trial for the entire cancer therapy field. Moving forward, the plan is to tailor immunotherapy regimens pre-surgery, with some individuals requiring combination therapies and others not.
Explore more on Sky News:
Warmest May and spring witnessed in UK history
Singer of “Agadoo” passes away suddenly
Glastonbury appearance for heroic Post Office worker?
The NHS is also reported to be trialing the vaccine, indicating a possible expansion in treatment accessibility.
According to the World Cancer Research Fund International, melanoma impacts upwards of 150,000 individuals around the globe annually.
[ad_2]
FAQs About the New Vaccine Treatment for Melanoma
Q: What is the overall survival rate with the new vaccine treatment for melanoma?
A: The new vaccine treatment for melanoma has an overall survival rate of 96%.
Q: Who is behind the creation of this new cancer vaccine?
A: Moderna and Merck and Co. have collaborated to develop this cancer vaccine.
Q: Compared to Keytruda alone, what is the improvement with the vaccine and Keytruda combination?
A: The vaccine and Keytruda combination have shown a 49% reduction in the risk of recurrence or death and improved recurrence-free survival rates (75% with the combination vs. 55.6% with Keytruda alone).
Q: How does the mRNA vaccine technology work?
A: mRNA vaccine technology delivers instructions to cells to produce a specific protein that can provoke an immune response personalized to individual patients.
Q: What does the future hold for this combined treatment?
A: Merck and Moderna are advancing a late-stage study to investigate the effectiveness and broader application of their vaccine and Keytruda combination.
Q: Are there plans to expand the vaccine treatment availability?
A: The NHS is reported to be trialing the vaccine, suggesting that there could be wider availability in the future.
Q: How prevalent is melanoma globally?
A: Melanoma affects more than 150,000 people globally each year.
